The matter concerns promotional materials for Anktiva, both in a televised advertisement and in remarks offered by Dr. Patrick Soon-Shiong, the company’s Global Chief Scientific and Medical Officer and Executive Chairman, during a recent public discussion. The FDA, it appears, finds these presentations to be, shall we say, lacking in precise adherence to factual representation – a circumstance rarely conducive to lasting investor confidence.
The stock took a hit, naturally. Down nearly ten percent, if I recall correctly. I wasn’t panicked, exactly. More…mildly inconvenienced. I’ve learned over the years that these dips are often opportunities, little gifts disguised as financial setbacks. Though, admittedly, my definition of a “gift” is usually something that doesn’t require me to calculate risk tolerance.
The whole idea of “safety” is subjective, isn’t it? Everyone’s got their own definition. I look for companies that sell things people absolutely need, even when they’re pinching pennies. Not the latest gadget. Not artisanal coffee. Just…basic stuff. It’s not glamorous, but it’s less likely to disappear overnight. And frankly, I’m tired of being surprised.
The source of all this excitement? Weight loss drugs. Specifically, Mounjaro and Zepbound. Now, people have been trying to lose weight since, well, probably since there was weight to lose. But these aren’t your grandmother’s diet pills. These are serious medications, and they’re having a serious impact on Lilly’s bottom line. In 2025, these two drugs are expected to account for a whopping 56% of total revenue. That’s…concentrated. It’s a bit like building a skyscraper on a single foundation. Impressive, perhaps, but also potentially precarious.
These numbers, cold and precise, don’t speak of ambition or greed. They speak of prudence, perhaps. A director taking a portion of his reward, cashing out a piece of the prosperity. It’s a small harvest, in the grand scheme, but every grain counts.
The price they fetched was based on some rather complicated calculations involving weighted averages and market closes, but the gist is this: Ticho still has a goodly pile of shares left, worth a hefty $1.35 million. It’s enough to keep a small country afloat, or at least stock a very large pantry.
Shares of the company behind the USDC stablecoin fell as much as 18% at the start of trading in the U.S., ending a several-week period of growth that had more than doubled its value. Coinbase (COIN), a crypto platform that benefits from the stablecoin’s revenue, also saw its stock price drop around 8%.
The purveyors of data alchemy and artificial intelligence seemed caught in a general tech-stock breeze, but the news surrounding Palantir itself was… decidedly optimistic. One could almost suspect a deliberate attempt to confound the short-sighted.
The valuation, as reported, rests upon the price of $17.48 at the time of the transaction, a figure aligning closely with the market close of $17.51 on the twenty-third of March, 2026. A negligible variance, one might observe, yet the market, like a fickle mistress, demands precision.
Nvidia, the name now whispered with reverence (and a certain calculating avarice), has become the indispensable artery of this digital expansion. Its graphical processing units, initially conceived for the rendering of illusory worlds, now serve as the very loom upon which the fabric of artificial intelligence is woven. The demand is not simply high; it is a relentless, almost desperate scramble for access to a finite resource. And in this scarcity lies both opportunity and, one might cautiously suggest, a certain moral weight.